MY HEALTH —
Your health data should tell one story.
Bring symptoms, labs, biometrics, habits, medication history, and KAP progress into one understandable view—without living inside five different apps.
TODAY
dataWhole-person snapshot
7-DAY VIEW
Energy + sleep
EnergySleep quality
What changed this week?
Biology
Sleep consistency improved while morning glucose remained stable.
Experience
Two higher-stress days aligned with lower energy check-ins.
Connection
Outdoor time and social connection were logged on the two highest-mood days.
These are associations in sample data—not diagnoses or proof of causation.
MEDICATION DEEP DIVE
Your health story, connected.
Bring together what you take, what you have experienced, and when things changed. Guided Prana does the digging behind the scenes and turns it into one understandable story.
01
What are you taking?
02
What have you been experiencing?
Tell us anything you have noticed—even if you have no idea whether it is related. This is especially useful if you are new and do not have records connected yet.
Intake formsSession notesMember check-insFullscript labs + supplementsBiometrics
Connected records are included automatically. You can always add something yourself.
What stands out in your health history
Your medication history and connected health records will be summarized here.
The review looks for timing, symptom overlap, interactions, laboratory and biometric context, and reported medication effects so the pattern can be viewed as a whole.
THE TIMELINE
See what changed—and when
This can be one of the most revealing views: medication starts and dose changes alongside the first appearance of symptoms, reactions, labs and biometric changes.
Medication startedMedication exposure began
Depressed mood documentedInitial intake
Anxiety + dizziness documented7/29 session note
Insomnia + fatigue + brain fog documented8/06 session note
Palpitations documented8/11 session note
The patterns worth looking at
Sleep, energy + thinking
Insomnia, fatigue, dizziness, headache and cognitive complaints appear in your history. The review engine checks these against known and reported medication effects, your other medications and supplements, relevant labs, and changes over time.
Sexual + hormonal effects
Sexual changes can be easy to miss or never brought up during a visit. They are included automatically when they appear in your records or when you report them yourself.
Heart + nervous-system signals
Palpitations, tremor, agitation, blood-pressure changes and other nervous-system or cardiac signals are reviewed together with dose, duration, other substances and available biometrics.
Unusual and easily overlooked reports
The search does not stop at common side effects. It also includes rare events, postmarketing reports, case literature, withdrawal effects and other reported signals that may be relevant to your story.
More than a side-effect list
This review combines your medication history with prescriptions, supplements, Fullscript data, laboratory findings, biometrics, symptoms, intake forms and provider-session notes. The goal is to surface combinations and patterns that are easy to miss when each part of your health is viewed separately.
Medication + medicationPotential additive effects and interactions
Medication + supplementsRelevant combinations from your actual regimen
Medication + labsResults that may add context to symptoms or monitoring
Medication + biometricsSleep, heart rate, HRV, blood pressure and other available trends
What is known about use at your duration?
Your entered duration: 22 years. For the medication and indication you entered, this section shows how long it has been studied, findings from longer follow-up, reports after prolonged exposure, and where long-term evidence is limited.
Reported events after use are included even when causation has not been established, so you can see the fuller safety picture rather than only the most common effects.
COMPLETE EVIDENCEShow me everything behind this review+
This is the source trail behind the review. It includes the common effects people usually hear about, plus uncommon, rare, postmarketing, withdrawal, long-exposure, interaction, and case-report findings that can otherwise be easy to miss.
Reported after use does not automatically mean caused by the medication. The point is to make the full reported safety picture visible so relevant patterns can be discussed with medical staff.
Mood, thinking + nervous system
- Trouble sleeping or sleeping too much
- Fatigue, low energy or unusual drowsiness
- Anxiety, agitation or feeling keyed up
- Difficulty concentrating, brain fog or memory problems
- Headache or dizziness
- Tremor or shaking
- Feeling intensely restless or unable to sit still (akathisia; reported after use)
- Involuntary movements or muscle jerks (movement disorders / myoclonus; reported after use)
- Mania or hypomania
- Seizures
- Confusion or delirium
Heart + circulation
- Palpitations or awareness of heartbeat
- Changes in blood pressure
- Fainting or near-fainting
- Changes in the heart's electrical rhythm (QT prolongation)
- Serious abnormal rhythms, including torsade de pointes (reported after use)
- Ventricular rhythm disturbances (reported after use)
- Bleeding or bruising more easily, especially with other medicines that affect bleeding
Digestion + appetite
- Nausea or vomiting
- Diarrhea
- Constipation
- Dry mouth
- Indigestion or abdominal discomfort
- Appetite or weight changes
- GI bleeding (reported after use / interaction concern)
- Pancreatitis (reported after use)
Sexual + hormonal
- Lower libido or reduced sexual interest
- Delayed or difficult orgasm
- Ejaculation delay or disorder
- Erectile or other sexual-function changes
- Breast-milk production or high prolactin when not expected (hyperprolactinemia; reported after use)
- Menstrual or reproductive changes reported in some users
Kidneys + urination
- Urinating more often or producing more urine
- Urinary urgency or incontinence
- Difficulty urinating or urinary retention
- Burning or pain with urination
- Blood in the urine
- Urinating much less than usual
- Kidney pain, stones or kidney infection reports
- Acute kidney failure (reported after use)
Muscles, joints + movement
- Muscle pain or aching
- Joint pain
- Muscle weakness or cramps
- Restlessness or abnormal movements
- Severe muscle breakdown that can injure the kidneys (rhabdomyolysis; reported after use)
Eyes, ears + senses
- Blurred or changed vision
- Eye pain, light sensitivity or difficulty focusing
- Dry or unusually watery eyes
- Dilated pupils
- Double vision
- Ringing in the ears (tinnitus)
- Changes or loss of taste
- Corneal inflammation or cataract reports
- Angle-closure glaucoma in susceptible people
Skin, hair + allergic reactions
- Rash or itching
- Increased sweating
- Hair loss or unusual hair changes
- Swelling of the face or extremities
- Serious allergic reaction / anaphylaxis (reported after use)
Breathing + respiratory
- Cough or bronchitis-like symptoms
- Shortness of breath
- Asthma-like symptoms or bronchospasm
- Pneumonia or pneumonitis reports
- Laryngitis or increased mucus / sputum reports
Other serious or easily missed findings
- Low blood sodium, which can show up as headache, confusion, weakness, memory problems or seizures (hyponatremia)
- Serotonin syndrome
- Withdrawal / discontinuation symptoms after dose reduction or stopping
- Serious liver injury, including liver-cell death reports
- Major allergic reactions
- Interaction-related effects when combined with other prescriptions, supplements, alcohol or substances
Where the review looks
Prescribing informationWarnings, adverse reactions, uncommon and rare events, monitoring and discontinuation information.
Postmarketing safety reportsEvents reported after a medication reached wider use, including rare signals that may not have appeared in trials.
Published literatureClinical studies, observational research, case reports and longer-follow-up findings.
Interaction referencesDrug–drug, drug–supplement, substance and additive-effect checks, including supplemental cross-checks such as Drugs.com.
Exposure-duration evidenceHow long treatment was actually studied, what is known from longer use, and where evidence becomes thin.
Your own recordSymptoms, dates, dose changes, labs, supplements, biometrics, intake information and session-note mentions.
Create my clinician handoff
Turn the full review into a concise document your medical provider can scan quickly: medication history, symptom chronology, relevant overlaps, interactions, labs and biometrics, duration context, monitoring considerations and supporting sources.
MEDICATION REVIEW
Clinician handoff
Patient-centered medication history + symptom chronology + safety evidence
Clinical snapshot
Medicationcitalopram
Reason takendepression
Exposure22 years
Current doseNot entered
Records considered: member-entered symptoms, intake forms, authorized session notes, medication timeline, available prescriptions/supplements, Fullscript data, labs and biometrics.
Why this review deserves attention
The current record contains symptoms that overlap with known or reported citalopram effects. Several also appear repeatedly across different source types, making the chronology worth reviewing as one story rather than as isolated complaints.
How this health information entered the report
Structured intake: demo / awaiting completion
Uploaded forms: not connected in this version
Session notes: not connected in this version
Fullscript: planned / not connected
Labs / biometrics: demo / manually entered only
1. What the patient's timeline shows
Medication exposure began: 22 years ago.
Symptoms documented afterward: depressed mood, insomnia, fatigue, brain fog, headache, dizziness, nausea, sexual dysfunction, muscle pain, palpitations and urinary symptoms.
Timing can make a pattern visible. It does not, by itself, establish that a medication caused an event.
2. Medication in the context of this patient's health
For citalopram, the current record contains several symptom overlaps that are directly described in labeling or professional adverse-effect references. The report also checks the patient's duration, other substances, laboratory context and physiologic data rather than treating the medication as an isolated variable.
Symptoms that overlap
- Insomnia — listed in placebo-controlled trials and discontinuation data.
- Fatigue — reported in placebo-controlled trials.
- Dizziness — appears in discontinuation data and professional adverse-effect references.
- Sexual dysfunction — specifically addressed in labeling; decreased libido, ejaculation disorder and impotence were reported in trials.
- Muscle pain — myalgia and arthralgia were reported in trials.
- Urinary symptoms — polyuria, frequency, incontinence, retention and dysuria appear in premarketing adverse-event listings.
- Palpitations — clinically important because citalopram can prolong QT and labeling tells patients to report palpitations/fainting.
Possible interactions
No individualized interaction conclusion is shown yet because a complete medication/supplement list has not been imported into this sample record.
Key interaction categories for citalopram include other serotonergic agents, QT-prolonging drugs, CYP2C19 inhibitors, and agents that increase bleeding risk such as NSAIDs, antiplatelets and anticoagulants.
Labs + biometrics
No connected lab values are present in this sample. When values are present, the review places relevant sodium, electrolytes, liver findings, blood pressure, heart-rate/rhythm data, sleep and other biometrics on the same timeline.
Exposure over time
The FDA-approved label established acute efficacy in 4–6 week trials and relapse-prevention benefit over the subsequent 6 months in continuation studies. That is very different from a single person taking citalopram continuously for 22 years. Long exposure should therefore be described as long-term real-world use with much thinner controlled-trial evidence at that duration.
3. Findings to discuss with the prescriber
Sleep, energy + cognition
Insomnia, fatigue, dizziness, headache and cognitive complaints appear in this record. Citalopram labeling reports insomnia, somnolence, fatigue, dizziness and other nervous-system effects. “Brain fog” is not a single label term, but overlapping descriptions include impaired concentration, confusion, amnesia and symptoms that can occur with hyponatremia.
Sexual effects
Sexual changes should not be treated as incidental. The current label specifically warns about sexual dysfunction. In short-term trials, decreased libido, ejaculation disorder and impotence were reported more often with citalopram than placebo.
Cardiac / autonomic signal
Palpitations deserve context because citalopram produces dose-dependent QTc prolongation and postmarketing reports include torsade de pointes and ventricular arrhythmias. Risk is more relevant with high doses, electrolyte abnormalities, heart disease, or other QT-prolonging drugs.
Urinary + renal signal
Urinary complaints are easy to miss in medication reviews. Premarketing listings include polyuria, urinary frequency, incontinence, retention and dysuria; rare reports included hematuria, oliguria, pyelonephritis, renal calculus and renal pain. Acute renal failure has also been reported postmarketing.
Rare / postmarketing findings that remain visible
The evidence review also retains serious or uncommon signals such as serotonin syndrome, hyponatremia, bleeding, seizures, angle-closure glaucoma, pancreatitis, rhabdomyolysis, hepatic injury, thrombocytopenia and arrhythmias. Their presence in a safety database does not prove causation in this patient, but it prevents rare events from disappearing simply because they were uncommon.
Discontinuation / withdrawal context
Citalopram labeling recognizes a discontinuation syndrome after dose reduction or stopping, including nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus and seizures. Any medication change should therefore be discussed with the prescriber rather than interpreted as a simple on/off switch.
4. Complete medication evidence
This section shows the evidence categories that matter to this patient's review rather than only the most common commercial side-effect list.
Short-term trial dataNausea 21% vs 14% placebo; dry mouth 20% vs 14%; somnolence 18% vs 10%; insomnia 15% vs 14%; anxiety 4% vs 3%; decreased libido 2% vs <1%; tremor 8% vs 6%; ejaculation disorder 6% vs 1%; impotence 3% vs <1%; fatigue 5% vs 3%; arthralgia and myalgia 2% vs 1%.
Warnings / precautionsQT prolongation/torsade de pointes, serotonin syndrome, bleeding, mania/hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatremia and sexual dysfunction.
Premarketing less-common eventsIncludes urinary frequency/incontinence/retention/dysuria, abnormal vision/eye pain, tinnitus, palpitations and additional neurologic, GI, endocrine, skin and musculoskeletal events.
PostmarketingVoluntary reports include serious cardiac rhythm events, thrombocytopenia/hemolytic anemia, pancreatitis, rhabdomyolysis, hepatic injury, acute renal failure and other rare signals. Frequency and causation often cannot be established from voluntary reports alone.
Exposure-duration evidenceAcute efficacy trials were 4–6 weeks. Continuation studies followed responders for another 6 months. The label also summarizes thousands of clinical-trial exposures and more than 19,000 mostly open-label European postmarketing exposures, but these data do not equal controlled evidence for 22 continuous years in one patient.
Interaction evidenceImportant categories include serotonergic drugs/supplements, QT-prolonging drugs, CYP2C19 inhibitors, and drugs that increase bleeding risk. The patient's actual regimen should be checked item-by-item.
Important evidence distinction
“Reported after use” means the event was observed or reported after exposure. It does not automatically mean the medication caused it. This report keeps those signals visible while labeling them according to the strength and type of evidence.
5. Specific points for the next visit
Appendix A — Patient chronology
~22 years agoCitalopram exposure began.
Initial intakeDepressed mood documented.
7/29 sessionAnxiety and dizziness documented.
8/06 sessionInsomnia, fatigue and brain fog documented.
8/11 sessionPalpitations documented.
Appendix B — Evidence behind each finding
Appendix C — References
- FDA / AbbVie. CELEXA (citalopram) Prescribing Information, 2024. Primary regulatory source for indication, warnings, trial adverse-event rates, postmarketing experience, interactions, discontinuation syndrome and clinical-study duration.
- DailyMed. Citalopram tablet labeling, updated 2026. Current structured labeling source used to cross-check adverse reactions and safety language.
- Drugs.com. Citalopram Side Effects, medically reviewed; updated 2025. Supplemental professional/consumer cross-check that organizes common, uncommon, rare, frequency-unknown and postmarketing effects by body system.
- Drugs.com. Citalopram Interactions Checker. Supplemental interaction cross-check; individualized conclusions require the patient's complete medication, OTC, supplement and substance list.
COMPARE APPROACHES
Growing libraryExplore mental + physical health from both sides.
Search by symptom, diagnosis, or body system. Every topic opens a side-by-side view of common conventional care and integrative/holistic approaches, with benefits, risks, limitations, and questions worth asking.
Educational comparison only. A symptom can have many causes, and an approach that is appropriate for one person may be inappropriate for another. This library does not diagnose, prescribe, or advise starting or stopping treatment. Evidence and risks vary by intervention and individual circumstances.
BIOMETRICS
dataSee trends without chasing numbers.
Glucose
92mg/dL7-day range 78–118
Ketones
1.2mmol/L7-day range 0.6–1.8
Blood Pressure
108/72mmHg3 readings this week
Resting HR
61bpmDown 3 bpm this month
HRV
54msPersonal range 42–67
Sleep
7h 42mlast night82% consistency
Planned data sources
Future versions may connect Apple Health / Apple Watch, Oura, compatible CGMs, blood-pressure monitors, ketone data, Fullscript, and other supported sources. These connections are not live in this version.
LABS
FullscriptFunctional data, connected to context.
HTMA
ReviewedMay 18Mineral balance + patterns
OAT
Example resultJun 07Organic acids
HORMONES
Not ordered—DUTCH / hormone testing
ENVIRONMENT
AvailableAs indicatedMycoTOX / environmental testing
How this should work
Guided Prana provides the understandable front door. Fullscript remains the lab and supplement infrastructure underneath it, avoiding a duplicate lab portal or another paid EHR simply for functional testing.
Fullscript integration coming laterPATTERNS + INSIGHTS
Put the numbers beside the lived experience.
Sleep ↔ mood
Higher mood ratings tended to follow nights with more consistent sleep in this demo period.
Stress ↔ HRV
Lower HRV appeared on the two days with the highest reported stress.
Meals ↔ glucose
Post-meal glucose responses can eventually be viewed next to food logs rather than in a separate CGM app.
Not one-variable medicine.
Biology, psychology, ecology, experience, and connection can be viewed together without pretending one number explains the whole person.
Pattern detection should identify correlations and trends, not diagnose conditions or claim causation.
MY PLAN
Keep the plan connected to the reason behind it.
Sleep consistency
Target a consistent sleep window and track subjective sleep quality alongside wearable data.
Nutrition + metabolic experiment
Track the intervention, the reason for trying it, and what actually changes over time.
Supplement plan
Link to the current Fullscript recommendation rather than duplicating supplement fulfillment.
Psychotherapy focus
Keep clinical goals visible without turning the wellness dashboard into an EHR.
KAP
Prepare. Experience. Integrate.
My intention
“Be more present and connected to what matters.”
Environment
Lighting, eye mask, BP cuff, headphones, comfort items, hydration, journal, and other supports.
Music
Curated playlist links and headphone recommendations can live here.
Session reflections
Capture insights, themes, body sensations, questions, and actions without forcing meaning too quickly.
Curated KAP gear
Contextual recommendations for items such as lighting, blood-pressure cuffs, eye masks, headphones, blankets, journals, and immersive tools can include clearly disclosed affiliate links.
Affiliate disclosure: Some product links may be affiliate links. Guided Prana may earn a commission at no additional cost to the purchaser.
CHECK-INS
Track what a wearable cannot measure.
CONNECTIONS
One front door. Specialized tools underneath.
Fullscript
Planned connection for labs, supplements, and supported wearable data.
PlannedHeadway
Psychotherapy scheduling, forms, client portal, billing, and clinical documentation.
External clinical systemCGM + ketones
Planned connection for compatible metabolic data sources without duplicate manual entry.
PlannedGuided Prana
The experience layer: education, patterns, KAP, whole-person context, and navigation.
Owned platform